Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy With or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
07
05
2021
accepted:
22
02
2022
pubmed:
24
3
2022
medline:
7
7
2022
entrez:
23
3
2022
Statut:
ppublish
Résumé
This retrospective multicenter cohort study compared the feasibility and safety of oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy (PIPAC-Ox) with or without intraoperative intravenous 5-fluorouracil (5-FU) and leucovorin (L). Our study included consecutive patients with histologically proven unresectable and isolated colorectal peritoneal metastases (cPM) treated with PIPAC-Ox in seven tertiary referral centers between January 2015 and April 2020. Toxicity events and oncological outcomes (histological response, progression-free survival, and overall survival) were compared between patients who received intraoperative intravenous 5-FU/L (PIPAC-Ox + 5-FU/L group) and patients who did not (PIPAC-Ox group). In total, 101 patients (263 procedures) were included in the PIPAC-Ox group and 30 patients (80 procedures) were included in the PIPAC-Ox + 5-FU/L group. Common Terminology Criteria for Adverse Events v4.0 grade 2 or higher adverse events occurred in 48 of 101 (47.5%) patients in the PIPAC-Ox group and in 13 of 30 (43.3%) patients in the PIPAC-Ox + 5-FU/L group (p = 0.73). The complete histological response rates according to the peritoneal regression grading score were 27% for the PIPAC-Ox + 5-FU/L group and 18% for the PIPAC-Ox group (p = 0.74). No statistically significant differences were observed in overall or progression-free survival between the two groups. The safety and feasibility of PIPAC-Ox + 5-FU/L appears to be similar to the safety and feasibility of PIPAC-Ox alone in patients with unresectable cPM. Oncological outcomes must be evaluated in larger studies.
Sections du résumé
BACKGROUND
BACKGROUND
This retrospective multicenter cohort study compared the feasibility and safety of oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy (PIPAC-Ox) with or without intraoperative intravenous 5-fluorouracil (5-FU) and leucovorin (L).
METHODS
METHODS
Our study included consecutive patients with histologically proven unresectable and isolated colorectal peritoneal metastases (cPM) treated with PIPAC-Ox in seven tertiary referral centers between January 2015 and April 2020. Toxicity events and oncological outcomes (histological response, progression-free survival, and overall survival) were compared between patients who received intraoperative intravenous 5-FU/L (PIPAC-Ox + 5-FU/L group) and patients who did not (PIPAC-Ox group).
RESULTS
RESULTS
In total, 101 patients (263 procedures) were included in the PIPAC-Ox group and 30 patients (80 procedures) were included in the PIPAC-Ox + 5-FU/L group. Common Terminology Criteria for Adverse Events v4.0 grade 2 or higher adverse events occurred in 48 of 101 (47.5%) patients in the PIPAC-Ox group and in 13 of 30 (43.3%) patients in the PIPAC-Ox + 5-FU/L group (p = 0.73). The complete histological response rates according to the peritoneal regression grading score were 27% for the PIPAC-Ox + 5-FU/L group and 18% for the PIPAC-Ox group (p = 0.74). No statistically significant differences were observed in overall or progression-free survival between the two groups.
CONCLUSIONS
CONCLUSIONS
The safety and feasibility of PIPAC-Ox + 5-FU/L appears to be similar to the safety and feasibility of PIPAC-Ox alone in patients with unresectable cPM. Oncological outcomes must be evaluated in larger studies.
Identifiants
pubmed: 35318519
doi: 10.1245/s10434-022-11577-2
pii: 10.1245/s10434-022-11577-2
doi:
Substances chimiques
Aerosols
0
Oxaliplatin
04ZR38536J
Leucovorin
Q573I9DVLP
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
5243-5251Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022. Society of Surgical Oncology.
Références
Valderrama-Treviño AI, Barrera-Mera B, Ceballos-Villalva JC, Montalvo-Javé EE. Hepatic metastasis from colorectal cancer. Euroasian J Hepato-Gastroenterol. 2017;7(2):166–75.
doi: 10.5005/jp-journals-10018-1241
Riihimäki M, Hemminki A, Sundquist J, Hemminki K. Patterns of metastasis in colon and rectal cancer. Sci Rep. 2016;6:29765.
pubmed: 27416752
pmcid: 4945942
doi: 10.1038/srep29765
Abboud K, André T, Brunel M, Ducreux M, Eveno C, Glehen O, et al. Management of colorectal peritoneal metastases: expert opinion. J Visc Surg. 2019;156(5):377–9.
pubmed: 31466831
doi: 10.1016/j.jviscsurg.2019.08.002
Bushati M, Rovers KP, Sommariva A, Sugarbaker PH, Morris DL, Yonemura Y, et al. The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI). Eur J Surg Oncol. 2018;44(12):1942–8.
pubmed: 30075978
doi: 10.1016/j.ejso.2018.07.003
Chicago Consensus Working Group. The Chicago Consensus on peritoneal surface malignancies: management of colorectal metastases. Cancer. 2020;126(11):2534–40.
doi: 10.1002/cncr.32874
de Bree E, Michelakis D, Stamatiou D, Romanos J, Zoras O. Pharmacological principles of intraperitoneal and bidirectional chemotherapy. Pleura Peritoneum. 2017;2(2):47–62.
pubmed: 30911633
pmcid: 6405033
doi: 10.1515/pp-2017-0010
Solass W, Kerb R, Mürdter T, Giger-Pabst U, Strumberg D, Tempfer C, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol. 2014;21(2):553–9.
pubmed: 24006094
doi: 10.1245/s10434-013-3213-1
Alyami M, Hübner M, Grass F, Bakrin N, Villeneuve L, Laplace N, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20(7):e368–77.
pubmed: 31267971
doi: 10.1016/S1470-2045(19)30318-3
Lurvink RJ, Rovers KP, Nienhuijs SW, Creemers G-J, Burger JWA, de Hingh IHJ. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-OX) in patients with colorectal peritoneal metastases-a systematic review. J Gastrointest Oncol. 2021;12(Suppl 1):S242–58.
pubmed: 33968441
pmcid: 8100707
doi: 10.21037/jgo-20-257
Sgarbura O, Hübner M, Alyami M, Eveno C, Gagnière J, Pache B, et al. Oxaliplatin use in pressurized intraperitoneal aerosol chemotherapy (PIPAC) is safe and effective: a multicenter study. Eur J Surg Oncol. 2019;45(12):2386–91.
pubmed: 31092362
doi: 10.1016/j.ejso.2019.05.007
Dumont F, Passot C, Raoul J-L, Kepenekian V, Lelièvre B, Boisdron-Celle M, et al. A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy for advanced peritoneal metastases of gastrointestinal tract cancers. Eur J Cancer. 2020;140:37–44.
pubmed: 33039812
doi: 10.1016/j.ejca.2020.09.010
Tabchouri N, Buggisch J, Demtröder CR, Thiery J, Rezniczek G, Tempfer CB, et al. Pressurized intraperitoneal aerosol chemotherapy for colorectal peritoneal metastases. Ann Surg Oncol. 2021;28(9):5275–86.
pubmed: 33471267
doi: 10.1245/s10434-020-09508-0
Ellebæk SB, Graversen M, Detlefsen S, Lundell L, Fristrup CW, Pfeiffer P, et al. Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)-directed treatment of peritoneal metastasis in end-stage colo-rectal cancer patients. Pleura Peritoneum. 2020;5(2):20200109.
pubmed: 32566727
pmcid: 7292236
doi: 10.1515/pp-2020-0109
Kim G, Tan HL, Sundar R, Lieske B, Chee CE, Ho J, et al. PIPAC-OX: a phase I study of oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy in patients with peritoneal metastases. Clin Cancer Res. 2021;27(7):1875–81.
pubmed: 33148667
doi: 10.1158/1078-0432.CCR-20-2152
Rovers KP, Wassenaar ECE, Lurvink RJ, Creemers G-JM, Burger JWA, Los M, et al. Pressurized intraperitoneal aerosol chemotherapy (oxaliplatin) for unresectable colorectal peritoneal metastases: a multicenter, single-arm, phase II trial (CRC-PIPAC). Ann Surg Oncol. 2021;28(9):5311–26.
pubmed: 33544279
doi: 10.1245/s10434-020-09558-4
Hübner M, Grass F, Teixeira-Farinha H, Pache B, Mathevet P, Demartines N. Pressurized intraperitoneal aerosol chemotherapy—practical aspects. Eur J Surg Oncol. 2017;43(6):1102–9.
pubmed: 28431896
doi: 10.1016/j.ejso.2017.03.019
National Cancer Institute. Common terminology criteria for adverse events (CTCAE), version 4.0. Bethesda: National Cancer Institute; 2009.
Solass W, Sempoux C, Detlefsen S, Carr NJ, Bibeau F. Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the Peritoneal Regression Grading Score (PRGS). Pleura Peritoneum. 2016;1(2):99–107.
pubmed: 30911613
pmcid: 6328069
doi: 10.1515/pp-2016-0011
Sgarbura O, Villeneuve L, Alyami M, Bakrin N, Torrent JJ, Eveno C, et al. Current practice of pressurized intraperitoneal aerosol chemotherapy (PIPAC): Still standardized or on the verge of diversification? Eur J Surg Oncol. 2021;47(1):149–56.
pubmed: 32900609
doi: 10.1016/j.ejso.2020.08.020
Taibi A, Teixeira Farinha H, Durand Fontanier S, Sayedalamin Z, Hübner M, Sgarbura O. Pressurized intraperitoneal aerosol chemotherapy enhanced by electrostatic precipitation (ePIPAC) for patients with peritoneal metastases. Ann Surg Oncol. 2021;28(7):3852–60.
pubmed: 33216263
doi: 10.1245/s10434-020-09332-6
Demtröder C, Solass W, Zieren J, Strumberg D, Giger-Pabst U, Reymond M-A. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis. Colorectal Dis. 2016;18(4):364–71.
pubmed: 26400556
doi: 10.1111/codi.13130
Graversen M, Detlefsen S, Pfeiffer P, Lundell L, Mortensen MB. Severe peritoneal sclerosis after repeated pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC OX): report of two cases and literature survey. Clin Exp Metastasis. 2018;35(3):103–8.
pubmed: 29705882
doi: 10.1007/s10585-018-9895-9
Gauthier A, Mankouri F, Demoly P, Sgarbura O, Mirela Chiriac A. Hypersensitivity reactions to platinum-based compounds in the context of pressurized intraperitoneal aerosol chemotherapy (PIPAC): description and management. Allergy. 2021;76(6):1882–5.
pubmed: 33616981
doi: 10.1111/all.14679
Mariano G, Pocard M, Eveno C. PIPAC: 8 key points for a good practice with video. J Visc Surg. 2019;156(2):169–71.
pubmed: 30770295
doi: 10.1016/j.jviscsurg.2019.01.006
Cazauran J-B, Alyami M, Lasseur A, Gybels I, Glehen O, Bakrin N. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) procedure for non-resectable peritoneal carcinomatosis (with video). J Gastrointest Surg. 2018;22(2):374–5.
pubmed: 28900843
doi: 10.1007/s11605-017-3565-0
Winkler CS, Sandhu J, Pettke E, Merchea A, Fong Y, Kumara HMCS, et al. Pressurized intraperitoneal aerosol chemotherapy, a palliative treatment approach for patients with peritoneal carcinomatosis: description of method and systematic review of literature. Dis Colon Rectum. 2020;63(2):242–55.
pubmed: 31914116
doi: 10.1097/DCR.0000000000001565
Glatz T, Horvath P, Lang SA, Archid R, Nadiradze G. Staging laparoscopy and pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis: safe access to the abdomen. Pleura Peritoneum. 2019;4(1):20190004.
pubmed: 31198854
pmcid: 6545875
doi: 10.1515/pp-2019-0004
Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18(1):136–47.
pubmed: 10623704
doi: 10.1200/JCO.2000.18.1.136
Rothenberg ML. Efficacy of oxaliplatin in the treatment of colorectal cancer. Oncol (Williston Park). 2000;14(12 Suppl 11):9–14.
Theile D, Grebhardt S, Haefeli WE, Weiss J. Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. Biochem Pharmacol. 2009;78(11):1366–73.
pubmed: 19622348
doi: 10.1016/j.bcp.2009.07.006
Badrudin D, Sideris L, Leblond FA, Pichette V, Cloutier AS, Drolet P, et al. Rationale for the administration of systemic 5-FU in combination with heated intraperitonal oxaliplatin. Surg Oncol. 2018;27(2):275–9.
pubmed: 29937182
doi: 10.1016/j.suronc.2018.05.004
Quénet F, Elias D, Roca L, Goéré D, Ghouti L, Pocard M, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):25–266.
doi: 10.1016/S1470-2045(20)30599-4
Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe J-M, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27(5):681–5.
pubmed: 19103728
doi: 10.1200/JCO.2008.19.7160
Alyami M, Mercier F, Siebert M, Bonnot P-E, Laplace N, Villeneuve L, et al. Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2021;47(1):128–33.
pubmed: 31253545
doi: 10.1016/j.ejso.2019.06.028
Solass W, Sempoux C, Carr NJ, Bibeau F, Neureiter D, Jäger T, et al. Reproducibility of the peritoneal regression grading score for assessment of response to therapy in peritoneal metastasis. Histopathology. 2019;74(7):1014–24.
pubmed: 30687944
doi: 10.1111/his.13829
Achilli P, De Martini P, Ceresoli M, Mari GM, Costanzi A, Maggioni D, et al. Tumor response evaluation after neoadjuvant chemotherapy in locally advanced gastric adenocarcinoma: a prospective, multi-center cohort study. J Gastrointest Oncol. 2017;8(6):1018–25.
pubmed: 29299362
pmcid: 5750190
doi: 10.21037/jgo.2017.08.13
Bertheau P, Lerebours F, Mounier N, de Roquancourt A, Espié M, Clot P, et al. Prognostic significance of a combined clinicopathologic score for response to primary systemic therapy in locally advanced breast cancer. Oncol Rep. 2005;14(2):513–20.
pubmed: 16012739
Gruenberger T, Arnold D, Rubbia-Brandt L. Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival. Surg Oncol. 2012;21(4):309–15.
pubmed: 22884035
doi: 10.1016/j.suronc.2012.07.003
Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18(2):299–304.
pubmed: 17060484
doi: 10.1093/annonc/mdl386
Blazer DG, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26(33):5344–51.
pubmed: 18936472
doi: 10.1200/JCO.2008.17.5299
Passot G, You B, Boschetti G, Fontaine J, Isaac S, Decullier E, et al. Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis. Ann Surg Oncol. 2014;21(8):2608–14.
pubmed: 24668148
doi: 10.1245/s10434-014-3647-0
Taibi A, Lo Dico R, Kaci R, Naneix AL, Mathonnet M, Pocard M. Impact of preoperative chemotherapy on the histological response of patients with peritoneal metastases from colorectal cancer according to peritoneal regression grading score (PRGS) and TRG. Surg Oncol. 2020;33:158–63.
pubmed: 32561082
doi: 10.1016/j.suronc.2020.02.014
Benzerdjeb N, Durieux E, Tantot J, Isaac S, Fontaine J, Harou O, et al. Prognostic impact of combined progression index based on peritoneal grading regression score and peritoneal cytology in peritoneal metastasis. Histopathology. 2020;77(4):548–59.
pubmed: 32060943
doi: 10.1111/his.14092